Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2014-11-18 Interim / Quarterly Rep…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Third quarter 2014 report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Third Quarter 2014 Report' for PCI Biotech Holding ASA. It contains detailed operational reviews of clinical trials, financial statements (Income Statement, Balance Sheet, Cash Flow) for the third quarter and year-to-date 2014, and management commentary. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q3 2014
2014-11-18 English
PCI Biotech: Third quarter 2014 report
Report Publication Announcement Classification · 98% confidence The document text is very short (469 characters) and explicitly states: 'Please find attached the third quarter 2014 report for PCI Biotech Holding ASA.' This structure—a brief announcement pointing to an attached or linked report—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. Although it mentions a 'Third quarter 2014 report,' the document itself is the announcement of that report, not the comprehensive report (which would be classified as IR).
2014-11-18 English
PCI Biotech to present at the World Vaccine Congress Europe 2014
Report Publication Announcement Classification · 99% confidence The document is a short press release dated October 14, 2014, announcing that PCI Biotech will be presenting at the World Vaccine Congress Europe 2014. It details the presentation topic, time, and location, and provides company background. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about participation in an industry event, which does not fit neatly into the specific categories like AGM, DIRS, or DIV. Given the nature of the announcement (a general corporate update about participation in an external event), the most appropriate fallback category is Regulatory Filings (RNS), as it serves as a general corporate disclosure, although it is not a standard SEC filing. However, since it is a specific announcement about corporate activity (presentation at a conference), and not a general regulatory disclosure, it is best classified as a general announcement. Since there is no specific category for 'Conference Presentation Announcement', RNS (Regulatory Filings / General Announcements) is the best fit among the provided options for this type of non-standard corporate news release.
2014-10-14 English
PCI Biotech to present at SACHS Associates 14th Annual Biotech in Europe Forum
Regulatory Filings Classification · 95% confidence The document is a short press release announcing that PCI Biotech will be presenting at the SACHS Associates 14th Annual Biotech in Europe Forum. It details the date, time, location, and representative for the presentation. This type of announcement, which informs investors about participation in an external industry event or conference, does not fit the definitions for formal financial reports (10-K, IR, ER), management changes (MANG), or specific regulatory filings. It is a general corporate update related to investor relations and market visibility. Since it is not a specific filing type like AGM-R, DVA, or DIV, and it is an announcement rather than a detailed report, the most appropriate classification is the general Regulatory Filings category (RNS), which serves as a fallback for miscellaneous corporate announcements not covered elsewhere.
2014-09-30 English
PCI Biotech: Financial Calendar 2015
Regulatory Filings Classification · 90% confidence The document is titled 'PCI Biotech: Financial Calendar 2015' and lists future dates for key corporate events, specifically the release of quarterly reports and the Annual General Meeting (AGM). It is not the report itself, nor is it a transcript or a detailed presentation. It is an announcement detailing the schedule of future corporate disclosures. Since it announces the timing of the AGM, it relates to AGM information, but more broadly, it is a schedule announcement. Given the options, the most fitting category for a schedule of corporate events, especially one that includes the AGM date, is often captured under general regulatory announcements or specific event announcements. However, since it explicitly lists the date for the 'Annual General Meeting', and the document is very short (1129 chars), it functions as a notification about upcoming corporate events. If the document were the AGM presentation itself, it would be AGM-R. Since it is just the calendar, and it is a short announcement, it could be RNS, but given the specific mention of the AGM date, it is closely related to AGM information. However, the primary function is announcing the schedule of reports and the AGM. Since there isn't a specific 'Financial Calendar' code, and it is a short announcement about future events, RNS (Regulatory Filings) is the safest fallback, although it is closely related to AGM-R content. Re-evaluating the definitions: AGM-R is for 'Presentations and materials shared during the AGM'. This is a calendar. The most specific item mentioned is the AGM date. If we consider this an announcement *about* the AGM, AGM-R might be considered, but it's too broad. Given the structure, it's a general corporate announcement about future reporting dates. I will classify this as RNS as it is a general schedule announcement that doesn't fit the specific report types (10-K, IR, ER) or the specific event materials (AGM-R, DEF 14A).
2014-09-22 English
PCI Biotech: Second quarter and first half year 2014 results
Investor Presentation Classification · 95% confidence The document is titled 'Second Quarter and First Half 2014 Results' and is presented by the CEO and CFO of PCI Biotech. It contains detailed business updates, clinical trial progress, and market potential analysis. While it is a presentation, it serves as the primary communication of the company's interim financial and operational performance for the specified period. According to the definitions, this fits the 'Investor Presentation' (IP) category as it is a detailed presentation for investors focusing on strategy and market position, though it also functions as an interim update. Given the structure and content, 'Investor Presentation' is the most accurate classification. H1 2014
2014-08-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.